GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Science 37 Holdings Inc (NAS:SNCE) » Definitions » Forward Dividend Yield %

Science 37 Holdings (Science 37 Holdings) Forward Dividend Yield % : 0.00% (As of Jun. 06, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Science 37 Holdings Forward Dividend Yield %?

As of today (2024-06-06), the Forward Annual Dividend Yield of Science 37 Holdings is 0.00%.

As of today (2024-06-06), the Trailing Annual Dividend Yield of Science 37 Holdings is 0.00%.

SNCE's Forward Dividend Yield % is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.295
* Ranked among companies with meaningful Forward Dividend Yield % only.

Science 37 Holdings's Dividends per Share for the three months ended in Sep. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Science 37 Holdings's Forward Dividend Yield %

For the Health Information Services subindustry, Science 37 Holdings's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Science 37 Holdings's Forward Dividend Yield % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Science 37 Holdings's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Science 37 Holdings's Forward Dividend Yield % falls into.



Science 37 Holdings Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Science 37 Holdings  (NAS:SNCE) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Science 37 Holdings Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Science 37 Holdings's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Science 37 Holdings (Science 37 Holdings) Business Description

Traded in Other Exchanges
N/A
Address
800 Park Offices Drive, Suite 3606, Research Triangle Park, Durham, NC, USA, 27709
Science 37 Holdings Inc is engaged in the development of new and innovative treatments that impact patient lives. It enables universal access to patients and providers for clinical trials. Its Operating System is fused with networks of telemedicine investigators, mobile nurses, remote coordinators, patient communities and connected devices.
Executives
Troy Bryenton officer: Chief Technology Officer 800 PARK OFFICES DRIVE, SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Christine A Pellizzari officer: Chief Legal Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Autenried Paul Von director BRISTOL-MYERS SQUIBB COMPANY, 100 NASSAU PARK BOULEVARD, PRINCETON NJ 08543
Michael Shipton officer: Chief Commercial Officer 800 PARK OFFICES DRIVE SUITE 3606, RESEARCH TRIANGLE PARK NC 27709
Adam Goulburn director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Thermo Fisher Scientific Powder Us Holdings Corp. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Thermo Fisher Scientific Inc. 10 percent owner 168 THIRD AVENUE, WALTHAM MA 02451
Neil Tiwari director C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Darcy Forman officer: Chief Delivery Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
David Coman director, officer: Chief Executive Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Jonathan Cotliar officer: Chief Medical Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Steven Geffon officer: Chief Commercial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
De Silva Bhooshitha B. director PPD, INC., 929 NORTH FRONT STREET, WILMINGTON NC 28401
Mike Zaranek officer: Chief Financial Officer C/O LIFESCI ACQUISITION II CORP., 250 W 55TH STREET, #3401, NEW YORK NY 10019
Ppd, Inc. 10 percent owner 929 NORTH FRONT STREET, WILMINGTON NC 28401-3331